NCT07750067 — Sun Yat-sen University cancer immunotherapy trial
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
Registry record
| Registry ID | NCT07750067 ↗ |
|---|---|
| Lead sponsor | Sun Yat-sen University |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Melanoma Metastatic, NRAS Mutation |
| Enrollment | 37 participants (target) |
| Start date | 2026-04-01 |
| Primary completion | 2030-07-28 (est.) |
| Last registry update | 10 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07750067), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07750067?
NCT07750067 (Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma) is registered on ClinicalTrials.gov as Phase 2, sponsored by Sun Yat-sen University.
Is NCT07750067 recruiting?
As of the 2026-08-10 registry update, NCT07750067 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07750067?
The lead sponsor is Sun Yat-sen University.
What condition does NCT07750067 study?
The registered conditions are Melanoma Metastatic, NRAS Mutation. Primary completion is listed as 2030-07-28 (estimated).
Are results available for NCT07750067?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07750067.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.